Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups. (Q52893849)
Jump to navigation
Jump to search
scientific article published on 25 July 2011
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups. |
scientific article published on 25 July 2011 |
Statements
Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups. (English)
1 reference
Peter A Fasching
1 reference
Sibylle Loibl
1 reference
Michael Untch
1 reference
Gottfried E Konecny
1 reference
Stephan Hasmüller
1 reference
Annette Lebeau
1 reference
Rolf Kreienberg
1 reference
Oumar Camara
1 reference
Volkmar Müller
1 reference
Andreas du Bois
1 reference
Thorsten Kühn
1 reference
Elmar Stickeler
1 reference
Nadia Harbeck
1 reference
Cornelia Höss
1 reference
Steffen Kahlert
1 reference
Thomas Beck
1 reference
Werner Fett
1 reference
Keyur M Mehta
1 reference
Gunter von Minckwitz
1 reference
25 July 2011
1 reference
29
1 reference
25
1 reference
3351-3357
1 reference